24GUT540 : Meeting of Breast Cancer Patients and Pathologists
24GUT540: Opportunity for Breast Cancer Patients to Meet With a Pathologist to Review the Pathology Slides of Their Breast Samples
1 other identifier
interventional
20
1 country
1
Brief Summary
Historically, most pathologists have had little direct contact or communication with patients. In the past two decades, however, there has been a modest movement toward patient-pathologist visits in which pathologists review with patients their pathology slides. Very few studies of such encounters have been conducted. Most surveyed patients reported that the experience was positive and helpful to them. Our basic goal is to determine if such meetings are useful to patients; a secondary goal is to determine if such encounters are useful to, and practical for, pathologists.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable breast-cancer
Started Jul 2025
Typical duration for not_applicable breast-cancer
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 12, 2025
CompletedFirst Posted
Study publicly available on registry
June 27, 2025
CompletedStudy Start
First participant enrolled
July 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2028
July 22, 2025
July 1, 2025
1.9 years
May 12, 2025
July 17, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Participant self-rating of understanding of, and empowerment in relation to, their disease, as measured using pre and post-visit knowledge questionnaires, and survey after meeting with a pathologist.
Determine understanding improvement from pre-meeting questionnaires and after pathologist visit with post-visit questionnaires, as well as knowledge questionnaire for both timepoints. Knowledge Questionnaire: Primary Score: Total Score - Total # correct responses on the knowledge questions (12 items total). Survey for Patients after Meeting with Pathologist Primary Score: Item 1 Total Score - Responses will be coded on a 0-4 scale where 0=strongly disagree and 4=strongly agree, and the total will be calculated across items 'a' through 'j' of Item 1.
1-2 weeks
Secondary Outcomes (2)
Participant knowledge of their personal disease characteristics
1-2 weeks
Participant general knowledge of breast cancer pathology
1-2 weeks
Other Outcomes (3)
Participant ratings of helpfulness and other features of meeting with a pathologist such as comfort level with the meeting
1-2 weeks
Participant anxiety self-rating
1-2 weeks
Pathologist rating of patient benefit from the meeting and other features of the meeting such as degree to which rapport was established.
1-2 weeks
Study Arms (1)
Assessment of Patient understanding of Pathologist input
OTHERAssessment of patient understanding of, and sense of control regarding, their disease, and their perception of the potential benefit of having pathologists on their medical team.
Interventions
* Benefit Self-Rating Total Score (assessing patient's perceptions of anticipated and actual extent to which they benefitted from the meeting with the pathologist) * Knowledge Questionnaire Total Score (assessing accuracy of knowledge of their own diagnosis and the diagnostic process in general) * State-Trait Anxiety Inventory Form Y (Total Scores for state (current) and trait (general) anxiety)
Eligibility Criteria
You may qualify if:
- Must be at least 18 years of age.
- Patients must have completed initial diagnosis visit with oncologist or surgeon.
- Must have pathology slides and reports available for review.
- Must be able to speak English.
- Must be willing to participate in this research and will be provided with an information sheet.
- Pregnant women are eligible as this research poses no risk of physical harm to the participant.
You may not qualify if:
- Patients \<18 years of age.
- Patients with DCIS are ineligible.
- Adults who are unable to provide written signature.
- Patients from vulnerable patient populations, including infants, minors, those unable to provide informed consent, and those incarcerated or imprisoned at the time of enrollment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Edward J Gutmann, MD
Dartmouth-Hitchcock Medical Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 12, 2025
First Posted
June 27, 2025
Study Start
July 10, 2025
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
June 1, 2028
Last Updated
July 22, 2025
Record last verified: 2025-07